Warfarin - How Good Are we at Maintaining Target Range ?

University of Dundee5,000 enrolled

Overview

Patients with atrial fibrillation are often anticoagulated with Warfarin. Warfarin has a narrow therapeutic window requiring frequent monitoring. This study aims to investigate the incidence of adverse events in the "real world" for patients receiving Warfarin for lone atrial fibrillation.

Study Type

OBSERVATIONAL

Enrollment

5,000

Conditions

Atrial Fibrillation

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Prescription for Warfarin * Atrial Fibrillation Exclusion Criteria: * Other conditions associated with increased risk of embolisation e.g. rheumatic valve disease, atrial mixoma. * Conditions with increased risk of bleeding.

Locations (1)

Centre for Cardiovascular and Lung Biology, Univeristy of Dundee

Dundee, United Kingdom

Outcomes

Primary Outcomes

Bleeding Complication

Any bleeding event requiring hospitalisation and / or blood transfusion. Any death attributable to bleeding i.e. Intracerebral bleed.

Time frame: 10 years

Cardiovascular outcome

Ischaemic event e.g. Cerebral infarction / Myocardial infarction / death attributed to ischaemic event

Time frame: 10 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.